Abstract
Summary
Exocrine pancreatic insufficiency refers to a medical condition which is characterized by the deficiency of the exocrine pancreatic enzymes.
LPI (LP Information)' newest research report, the “Exocrine Pancreatic Insufficiency Therapeutic Industry Forecast” looks at past sales and reviews total world Exocrine Pancreatic Insufficiency Therapeutic sales in 2022, providing a comprehensive analysis by region and market sector of projected Exocrine Pancreatic Insufficiency Therapeutic sales for 2023 through 2029. With Exocrine Pancreatic Insufficiency Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Exocrine Pancreatic Insufficiency Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Exocrine Pancreatic Insufficiency Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Exocrine Pancreatic Insufficiency Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Exocrine Pancreatic Insufficiency Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Exocrine Pancreatic Insufficiency Therapeutic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Exocrine Pancreatic Insufficiency Therapeutic.
The global Exocrine Pancreatic Insufficiency Therapeutic market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Exocrine Pancreatic Insufficiency Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Exocrine Pancreatic Insufficiency Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Exocrine Pancreatic Insufficiency Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Exocrine Pancreatic Insufficiency Therapeutic players cover AbbVie, Janssen Pharmaceuticals, Allergan, AzurRx and CHIESI Farmaceutici S.p.A., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Exocrine Pancreatic Insufficiency Therapeutic market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Pancreatic Enzyme Replacement Therapy
Nutritional Therapy
Segmentation by application
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Janssen Pharmaceuticals
Allergan
AzurRx
CHIESI Farmaceutici S.p.A.
LPI (LP Information)' newest research report, the “Exocrine Pancreatic Insufficiency Therapeutic Industry Forecast” looks at past sales and reviews total world Exocrine Pancreatic Insufficiency Therapeutic sales in 2022, providing a comprehensive analysis by region and market sector of projected Exocrine Pancreatic Insufficiency Therapeutic sales for 2023 through 2029. With Exocrine Pancreatic Insufficiency Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Exocrine Pancreatic Insufficiency Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Exocrine Pancreatic Insufficiency Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Exocrine Pancreatic Insufficiency Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Exocrine Pancreatic Insufficiency Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Exocrine Pancreatic Insufficiency Therapeutic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Exocrine Pancreatic Insufficiency Therapeutic.
The global Exocrine Pancreatic Insufficiency Therapeutic market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Exocrine Pancreatic Insufficiency Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Exocrine Pancreatic Insufficiency Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Exocrine Pancreatic Insufficiency Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Exocrine Pancreatic Insufficiency Therapeutic players cover AbbVie, Janssen Pharmaceuticals, Allergan, AzurRx and CHIESI Farmaceutici S.p.A., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Exocrine Pancreatic Insufficiency Therapeutic market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Pancreatic Enzyme Replacement Therapy
Nutritional Therapy
Segmentation by application
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Janssen Pharmaceuticals
Allergan
AzurRx
CHIESI Farmaceutici S.p.A.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Exocrine Pancreatic Insufficiency Therapeutic Market Size 2018-2029
2.1.2 Exocrine Pancreatic Insufficiency Therapeutic Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Exocrine Pancreatic Insufficiency Therapeutic Segment by Type
2.2.1 Pancreatic Enzyme Replacement Therapy
2.2.2 Nutritional Therapy
2.3 Exocrine Pancreatic Insufficiency Therapeutic Market Size by Type
2.3.1 Exocrine Pancreatic Insufficiency Therapeutic Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Exocrine Pancreatic Insufficiency Therapeutic Market Size Market Share by Type (2018-2023)
2.4 Exocrine Pancreatic Insufficiency Therapeutic Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies & Drug Stores
2.4.3 Others
2.5 Exocrine Pancreatic Insufficiency Therapeutic Market Size by Application
2.5.1 Exocrine Pancreatic Insufficiency Therapeutic Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Exocrine Pancreatic Insufficiency Therapeutic Market Size Market Share by Application (2018-2023)
3 Exocrine Pancreatic Insufficiency Therapeutic Market Size by Player
3.1 Exocrine Pancreatic Insufficiency Therapeutic Market Size Market Share by Players
3.1.1 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue by Players (2018-2023)
3.1.2 Global Exocrine Pancreatic Insufficiency Therapeutic Revenue Market Share by Players (2018-2023)
3.2 Global Exocrine Pancreatic Insufficiency Therapeutic Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Exocrine Pancreatic Insufficiency Therapeutic by Regions
4.1 Exocrine Pancreatic Insufficiency Therapeutic Market Size by Regions (2018-2023)
4.2 Americas Exocrine Pancreatic Insufficiency Therapeutic Market Size Growth (2018-2023)
4.3 APAC Exocrine Pancreatic Insufficiency Therapeutic Market Size Growth (2018-2023)
4.4 Europe Exocrine Pancreatic Insufficiency Therapeutic Market Size Growth (2018-2023)
4.5 Middle East & Africa Exocrine Pancreatic Insufficiency Therapeutic Market Size Growth (2018-2023)
5 Americas
5.1 Americas Exocrine Pancreatic Insufficiency Therapeutic Market Size by Country (2018-2023)
5.2 Americas Exocrine Pancreatic Insufficiency Therapeutic Market Size by Type (2018-2023)
5.3 Americas Exocrine Pancreatic Insufficiency Therapeutic Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Exocrine Pancreatic Insufficiency Therapeutic Market Size by Region (2018-2023)
6.2 APAC Exocrine Pancreatic Insufficiency Therapeutic Market Size by Type (2018-2023)
6.3 APAC Exocrine Pancreatic Insufficiency Therapeutic Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Exocrine Pancreatic Insufficiency Therapeutic by Country (2018-2023)
7.2 Europe Exocrine Pancreatic Insufficiency Therapeutic Market Size by Type (2018-2023)
7.3 Europe Exocrine Pancreatic Insufficiency Therapeutic Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Exocrine Pancreatic Insufficiency Therapeutic by Region (2018-2023)
8.2 Middle East & Africa Exocrine Pancreatic Insufficiency Therapeutic Market Size by Type (2018-2023)
8.3 Middle East & Africa Exocrine Pancreatic Insufficiency Therapeutic Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.1 Global Exocrine Pancreatic Insufficiency Therapeutic Forecast by Regions (2024-2029)
10.1.1 Global Exocrine Pancreatic Insufficiency Therapeutic Forecast by Regions (2024-2029)
10.1.2 Americas Exocrine Pancreatic Insufficiency Therapeutic Forecast
10.1.3 APAC Exocrine Pancreatic Insufficiency Therapeutic Forecast
10.1.4 Europe Exocrine Pancreatic Insufficiency Therapeutic Forecast
10.1.5 Middle East & Africa Exocrine Pancreatic Insufficiency Therapeutic Forecast
10.2 Americas Exocrine Pancreatic Insufficiency Therapeutic Forecast by Country (2024-2029)
10.2.1 United States Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.2.2 Canada Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.2.3 Mexico Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.2.4 Brazil Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.3 APAC Exocrine Pancreatic Insufficiency Therapeutic Forecast by Region (2024-2029)
10.3.1 China Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.3.2 Japan Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.3.3 Korea Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.3.4 Southeast Asia Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.3.5 India Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.3.6 Australia Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.4 Europe Exocrine Pancreatic Insufficiency Therapeutic Forecast by Country (2024-2029)
10.4.1 Germany Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.4.2 France Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.4.3 UK Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.4.4 Italy Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.4.5 Russia Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.5 Middle East & Africa Exocrine Pancreatic Insufficiency Therapeutic Forecast by Region (2024-2029)
10.5.1 Egypt Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.5.2 South Africa Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.5.3 Israel Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.5.4 Turkey Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.5.5 GCC Countries Exocrine Pancreatic Insufficiency Therapeutic Market Forecast
10.6 Global Exocrine Pancreatic Insufficiency Therapeutic Forecast by Type (2024-2029)
10.7 Global Exocrine Pancreatic Insufficiency Therapeutic Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Exocrine Pancreatic Insufficiency Therapeutic Product Offered
11.1.3 AbbVie Exocrine Pancreatic Insufficiency Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 AbbVie Main Business Overview
11.1.5 AbbVie Latest Developments
11.2 Janssen Pharmaceuticals
11.2.1 Janssen Pharmaceuticals Company Information
11.2.2 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency Therapeutic Product Offered
11.2.3 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Janssen Pharmaceuticals Main Business Overview
11.2.5 Janssen Pharmaceuticals Latest Developments
11.3 Allergan
11.3.1 Allergan Company Information
11.3.2 Allergan Exocrine Pancreatic Insufficiency Therapeutic Product Offered
11.3.3 Allergan Exocrine Pancreatic Insufficiency Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Allergan Main Business Overview
11.3.5 Allergan Latest Developments
11.4 AzurRx
11.4.1 AzurRx Company Information
11.4.2 AzurRx Exocrine Pancreatic Insufficiency Therapeutic Product Offered
11.4.3 AzurRx Exocrine Pancreatic Insufficiency Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 AzurRx Main Business Overview
11.4.5 AzurRx Latest Developments
11.5 CHIESI Farmaceutici S.p.A.
11.5.1 CHIESI Farmaceutici S.p.A. Company Information
11.5.2 CHIESI Farmaceutici S.p.A. Exocrine Pancreatic Insufficiency Therapeutic Product Offered
11.5.3 CHIESI Farmaceutici S.p.A. Exocrine Pancreatic Insufficiency Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 CHIESI Farmaceutici S.p.A. Main Business Overview
11.5.5 CHIESI Farmaceutici S.p.A. Latest Developments
12 Research Findings and Conclusion